Adjuvance is a startup based in France.
Adjuvance develops a semi-synthetic process to mass-produce a superior version of the QS21 vaccine adjuvant, aiming to enhance vaccine efficacy where current solutions are suboptimal.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.